Skip to main content

Table 2 Adverse events associated with delta-8-THC reported by delta-8-THC users on Reddit delta-8-THC forum r/Delta8 by MedDRA Preferred Term

From: Self-reported adverse events associated with ∆8-Tetrahydrocannabinol (Delta-8-THC) Use

MedDRA Preferred Terms

Subcategory Prevalence

Anxiety

16.4% (95% CI: 12.8–20.6)

Cough

15.5% (95% CI: 11.6–19.4)

Paranoia

9.3% (95% CI: 6.3–12.2)

Accidental overdose

8.7% (95% CI: 5.7–11.9)

Heart rate increased

6.9% (95% CI: 4.5–9.9)

Panic attack

6.9% (95% CI: 4.2–9.6)

Dyspnoea

5.7% (95% CI: 3.3–8.4)

Headache

5.4% (95% CI: 3.0–7.8)

Nausea

5.4% (95% CI: 3.0–7.8)

Vomiting

5.4% (95% CI: 3.0–7.8)

Dizziness

5.1% (95% CI: 3.0–7.5)

Feeling abnormal

4.8% (95% CI: 2.7–7.2)

Throat irritationa

4.2% (95% CI: 2.1–6.6)

Pulmonary paina

3.9% (95% CI: 2.1–6.0)

Chest pain

3.6% (95% CI: 1.8–5.7)

Amnesia

3.3% (95% CI: 1.5–5.4)

Chest discomfort

3.0% (95% CI: 1.5–5.1)

Fatigue

3.0% (95% CI: 1.2–4.8)

Tremor

3.0% (95% CI: 1.2–4.8)

Depression

2.7% (95% CI: 0.9–4.5)

Panic reaction

2.7% (95% CI: 1.2–4.5)

Withdrawal syndrome

2.7% (95% CI: 1.2–4.5)

Disturbance in attention

2.4% (95% CI: 0.9–4.2)

Unevaluable event

2.4% (95% CI: 0.9–4.2)

Abnormal dreams

2.1% (95% CI: 0.6–3.6)

Insomnia

2.1% (95% CI: 0.6–3.9)

Decreased appetite

1.8% (95% CI: 0.6–3.3)

Hypoaesthesia

1.8% (95% CI: 0.6–3.3)

Chills

1.8% (95% CI: 0.6–3.3)

Depersonalisation/derealisation disorder

1.8% (95% CI: 0.6–3.3)

Somnolence

1.8% (95% CI: 0.6–3.3)

Dry mouth

1.8% (95% CI: 0.6–3.3)

Metamorphopsiaa

1.8% (95% CI: 0.6–3.6)

Dependencea

1.5% (95% CI: 0.3–3.0)

Increased appetitea

1.5% (95% CI: 0.3–3.0)

Diarrhoea

1.5% (95% CI: 0.3–3.0)

Head discomforta

1.5% (95% CI: 0.3–3.0)

Respiratory tract irritation

1.5% (95% CI: 0.3–3.0)

Productive cougha

1.5% (95% CI: 0.3–3.0)

Oropharyngeal pain

1.5% (95% CI: 0.3–2.7)

Abdominal pain upper

1.5% (95% CI: 0.3–2.7)

Abdominal discomfort

1.5% (95% CI: 0.3–3.0)

Hyperhidrosis

1.5% (95% CI: 0.3–3.0)

Muscle twitching

1.5% (95% CI: 0.3–3.0)

Time perception altered

1.5% (95% CI: 0.3–3.0)

Vision blurred

1.2% (95% CI: 0.3–2.4)

Drug withdrawal syndrome

1.2% (95% CI: 0.3–2.7)

Dysarthria

1.2% (95% CI: 0.3–2.4)

Hallucination, visual

1.2% (95% CI: 0.3–2.4)

Autoscopya

1.2% (95% CI: 0.3–2.7)

Abdominal pain

0.9% (95% CI: 0.0–2.1)

Hallucinations, mixed

0.9% (95% CI: 0.0–2.1)

Loss of consciousness

0.9% (95% CI: 0.0–1.8)

Hypertension

0.9% (95% CI: 0.0–2.1)

Ocular hyperaemia

0.9% (95% CI: 0.0–2.1)

Seizure

0.9% (95% CI: 0.0–2.1)

Disorientation

0.9% (95% CI: 0.0–1.8)

Dissociation

0.9% (95% CI: 0.0–1.8)

Irritability

0.9% (95% CI: 0.0–2.1)

Muscle spasms

0.9% (95% CI: 0.0–2.1)

Paraesthesia

0.9% (95% CI: 0.0–2.1)

Tinnitus

0.9% (95% CI: 0.0–2.1)

Sedation

0.9% (95% CI: 0.0–2.1)

Sneezinga

0.9% (95% CI: 0.0–2.1)

Vertigo

0.9% (95% CI: 0.0–2.1)

Pain

0.6% (95% CI: 0.0–1.5)

Agitation

0.6% (95% CI: 0.0–1.5)

Choking sensation

0.6% (95% CI: 0.0–1.5)

Delusion

0.6% (95% CI: 0.0–1.5)

Depressed mooda

0.6% (95% CI: 0.0–1.5)

Blood pressure increased

0.6% (95% CI: 0.0–1.5)

Thirst

0.6% (95% CI: 0.0–1.5)

Flatulencea

0.6% (95% CI: 0.0–1.5)

Hunger

0.6% (95% CI: 0.0–1.5)

Nervousness

0.6% (95% CI: 0.0–1.5)

Palpitations

0.6% (95% CI: 0.0–1.5)

Dysphemiaa

0.6% (95% CI: 0.0–1.5)

Bruxisma

0.6% (95% CI: 0.0–1.5)

Ill-defined disordera

0.6% (95% CI: 0.0–1.5)

Blepharospasma

0.6% (95% CI: 0.0–1.5)

Food cravinga

0.6% (95% CI: 0.0–1.5)

Presyncope

0.6% (95% CI: 0.0–1.5)

Tachyphrenia

0.6% (95% CI: 0.0–1.5)

Abnormal loss of weighta

0.6% (95% CI: 0.0–1.5)

Emotional povertya

0.6% (95% CI: 0.0–1.5)

Balance disorder

0.6% (95% CI: 0.0–1.5)

Sensory disturbance

0.3% (95% CI: 0.0–0.9)

Acnea

0.3% (95% CI: 0.0–0.9)

Hypersensitivity

0.3% (95% CI: 0.0–0.9)

Altered state of consciousness

0.3% (95% CI: 0.0–0.9)

Ammonia increaseda

0.3% (95% CI: 0.0–0.9)

Abdominal distensiona

0.3% (95% CI: 0.0–1.2)

Eye irritation

0.3% (95% CI: 0.0–0.9)

Tongue discomforta

0.3% (95% CI: 0.0–0.9)

Cold sweat

0.3% (95% CI: 0.0–0.9)

Constipation

0.3% (95% CI: 0.0–0.9)

Haemoptysisa

0.3% (95% CI: 0.0–0.9)

Formication

0.3% (95% CI: 0.0–0.9)

Dehydration

0.3% (95% CI: 0.0–0.9)

Non-24-h sleep–wake disordera

0.3% (95% CI: 0.0–0.9)

Dry eyea

0.3% (95% CI: 0.0–0.9)

Dry throata

0.3% (95% CI: 0.0–0.9)

Asthmaa

0.3% (95% CI: 0.0–0.9)

Burning sensation

0.3% (95% CI: 0.0–0.9)

Eye paina

0.3% (95% CI: 0.0–0.9)

Asthenopiaa

0.3% (95% CI: 0.0–0.9)

Fear

0.3% (95% CI: 0.0–0.9)

Feeling jittery

0.3% (95% CI: 0.0–0.9)

Feeling hot

0.3% (95% CI: 0.0–0.9)

Pyrexia

0.3% (95% CI: 0.0–0.9)

Photopsiaa

0.3% (95% CI: 0.0–1.2)

Hallucination

0.3% (95% CI: 0.0–0.9)

Hangovera

0.3% (95% CI: 0.0–0.9)

Hepatic encephalopathya

0.3% (95% CI: 0.0–0.9)

Urticaria

0.3% (95% CI: 0.0–0.9)

Psychomotor hyperactivity

0.3% (95% CI: 0.0–0.9)

Salivary hypersecretiona

0.3% (95% CI: 0.0–0.9)

Apathy

0.3% (95% CI: 0.0–0.9)

Hepatomegalya

0.3% (95% CI: 0.0–0.9)

Ageusiaa

0.3% (95% CI: 0.0–0.9)

Mood swings

0.3% (95% CI: 0.0–0.9)

Nasal discomforta

0.3% (95% CI: 0.0–0.9)

Rhinalgiaa

0.3% (95% CI: 0.0–0.9)

Neuralgiaa

0.3% (95% CI: 0.0–1.2)

Night sweats

0.3% (95% CI: 0.0–0.9)

Nightmarea

0.3% (95% CI: 0.0–0.9)

Epistaxis

0.3% (95% CI: 0.0–0.9)

Pain in extremitya

0.3% (95% CI: 0.0–0.9)

Painful respirationa

0.3% (95% CI: 0.0–0.9)

Illusion

0.3% (95% CI: 0.0–0.9)

Post-traumatic stress disorder

0.3% (95% CI: 0.0–0.9)

Eyelid ptosisa

0.3% (95% CI: 0.0–1.2)

Rhinorrhoeaa

0.3% (95% CI: 0.0–0.9)

Libido increaseda

0.3% (95% CI: 0.0–0.9)

Shock

0.3% (95% CI: 0.0–0.9)

Sinusitis

0.3% (95% CI: 0.0–0.9)

Sinus paina

0.3% (95% CI: 0.0–0.9)

Sleep attacksa

0.3% (95% CI: 0.0–0.9)

Poor quality sleep

0.3% (95% CI: 0.0–0.9)

Odynophagiaa

0.3% (95% CI: 0.0–0.9)

Swollen tongue

0.3% (95% CI: 0.0–0.9)

Pharyngeal swellinga

0.3% (95% CI: 0.0–0.9)

Throat tightness

0.3% (95% CI: 0.0–0.9)

Vascular paina

0.3% (95% CI: 0.0–0.9)

Visual impairment

0.3% (95% CI: 0.0–0.9)

Weight increaseda

0.3% (95% CI: 0.0–0.9)

Piloerectiona

0.3% (95% CI: 0.0–0.9)

Energy increaseda

0.3% (95% CI: 0.0–0.9)

Thirst decreaseda

0.3% (95% CI: 0.0–0.9)

Lazinessa

0.3% (95% CI: 0.0–0.9)

Perihepatic discomforta

0.3% (95% CI: 0.0–0.9)

Derealisationa

0.3% (95% CI: 0.0–0.9)

Negative thoughts

0.3% (95% CI: 0.0–0.9)

Rash

0.3% (95% CI: 0.0–1.2)

Tooth deposita

0.3% (95% CI: 0.0–0.9)

Neurological symptoma

0.3% (95% CI: 0.0–0.9)

Photophobiaa

0.3% (95% CI: 0.0–0.9)

Intra-abdominal fluid collectiona

0.3% (95% CI: 0.0–0.9)

Gastrooesophageal reflux disease

0.3% (95% CI: 0.0–1.2)

Paralysis

0.3% (95% CI: 0.0–0.9)

Hyperacusisa

0.3% (95% CI: 0.0–1.2)

Secretion dischargea

0.3% (95% CI: 0.0–0.9)

Appetite disordera

0.3% (95% CI: 0.0–0.9)

Sputum discoloureda

0.3% (95% CI: 0.0–0.9)

Urinary retentiona

0.3% (95% CI: 0.0–0.9)

Pneumonitisa

0.3% (95% CI: 0.0–0.9)

Oropharyngeal discomforta

0.3% (95% CI: 0.0–0.9)

Rash erythematousa

0.3% (95% CI: 0.0–1.2)

Axillary paina

0.3% (95% CI: 0.0–0.9)

  1. aIndicates a MedDRA preferred term that was not listed in a FAERS case
  2. Abbreviations: FAERS Food and Drug Administration Adverse Event Reporting System, MedDRA Medical Dictionary for Regulatory Activities